Largest pharmaceutical companies in the United States by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Pfizer leads the 44 pharmaceutical companies in the United States ranked by net assets, at NOK 842.9B, ahead of Johnson & Johnson (NOK 794.9B) and Merck & Co (NOK 512.8B). Figures as of 20 Nov 2026, 06:58 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 44
- First
- PfizerNOK 842.9B
- Median
- NOK 6.4B
- Combined market value
- NOK 36.42T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | PfizerPFE · Health Care | NOK 842.9B | NOK 1.53T | NOK 268.45 | 1.85% down | 15% up | ||
| 2 | Johnson & JohnsonJNJ · Health Care | NOK 794.9B | NOK 6.27T | NOK 2,604.00 | 2.04% down | 34% up | ||
| 3 | Merck & CoMRK · Health Care | NOK 512.8B | NOK 3.19T | NOK 1,294.59 | 3.61% down | 45% up | ||
| 4 | Abbott LaboratoriesABT · Health Care | NOK 508.1B | NOK 1.75T | NOK 1,012.49 | 0.58% down | 16% down | ||
| 5 | Regeneron PharmaceuticalsREGN · Health Care | NOK 304.7B | NOK 931.1B | NOK 9,000.45 | 2.35% down | 28% up | ||
| 6 | Eli LillyLLY · Health Care | NOK 258.7B | NOK 11.73T | NOK 13,170.33 | 2.29% down | 33% up | ||
| 7 | Vertex PharmaceuticalsVRTX · Health Care | NOK 181.9B | NOK 1.29T | NOK 5,075.24 | 2.94% down | 27% up | ||
| 8 | Bristol-Myers SquibbBMY · Health Care | NOK 180.1B | NOK 1.16T | NOK 568.68 | 2.05% down | 30% up | ||
| 9 | ViatrisVTRS · Health Care | NOK 143.4B | NOK 222.2B | NOK 193.78 | 1.97% down | 99% up | ||
| 10 | Royalty PharmaRPRX · Health Care | NOK 94.7B | NOK 379.6B | NOK 660.11 | 1.38% down | 79% up | ||
| 11 | United TherapeuticsUTHR · Health Care | NOK 69.2B | NOK 232.1B | NOK 5,449.94 | 3.16% down | 22% up | ||
| 12 | Elanco Animal HealthELAN · Health Care | NOK 63.8B | NOK 128.1B | NOK 256.27 | 1.54% down | 26% up | ||
| 13 | BioMarin PharmaceuticalBMRN · Health Care | NOK 59.3B | NOK 116B | NOK 598.70 | 0.02% down | 17% up | ||
| 14 | ZoetisZTS · Health Care | NOK 32.5B | NOK 320B | NOK 787.52 | 5.59% down | 26% down | ||
| 15 | Ligand PharmaceuticalsLGND · Health Care | NOK 9.9B | NOK 55.9B | NOK 2,797.01 | 3.94% down | 50% up | ||
| 16 | Legend BiotechLEGN · Health Care | NOK 9.8B | NOK 30.4B | NOK 156.94 | 0.92% down | 41% down | ||
| 17 | Praxis Precision MedicinesPRAX · Health Care | NOK 8.6B | NOK 84.7B | NOK 3,030.56 | 1.87% up | 86% up | ||
| 18 | Alnylam PharmaceuticalsALNY · Health Care | NOK 7.7B | NOK 193B | NOK 1,440.91 | 1.06% down | 66% down | ||
| 19 | Belite BioBLTE · Health Care | NOK 7.5B | NOK 59.8B | NOK 1,472.10 | 3.33% down | 43% up | ||
| 20 | InsmedINSM · Health Care | NOK 7.2B | NOK 308.9B | NOK 1,408.15 | 20.58% up | 40% down | ||
| 21 | Spyre TherapeuticsSYRE · Health Care | NOK 7B | NOK 90.4B | NOK 951.67 | 3.77% down | 332% up | ||
| 22 | Summit TherapeuticsSMMT · Health Care | NOK 6.4B | NOK 82.4B | NOK 103.03 | 0.67% up | 36% down | ||
| 23 | TG TherapeuticsTGTX · Health Care | NOK 6.3B | NOK 95.6B | NOK 632.43 | 1.88% down | 117% up | ||
| 24 | Corcept TherapeuticsCORT · Health Care | NOK 6.3B | NOK 69.3B | NOK 633.41 | 4.15% down | 10% down | ||
| 25 | Cogent BiosciencesCOGT · Health Care | NOK 6.2B | NOK 47B | NOK 270.40 | 0.25% down | 20% down | ||
| 26 | Protagonist TherapeuticsPTGX · Health Care | NOK 6B | NOK 78.9B | NOK 1,208.91 | 2.47% down | 51% up | ||
| 27 | Madrigal PharmaceuticalsMDGL · Health Care | NOK 5.9B | NOK 89.8B | NOK 3,867.31 | 0.34% down | 27% down | ||
| 28 | Edgewise TherapeuticsEWTX · Health Care | NOK 5.1B | NOK 43.9B | NOK 401.31 | 0.48% down | 86% up | ||
| 29 | Dianthus TherapeuticsDNTH · Health Care | NOK 4.8B | NOK 46.6B | NOK 826.90 | 1.01% up | 108% up | ||
| 30 | Ionis PharmaceuticalsIONS · Health Care | NOK 4.8B | NOK 44.2B | NOK 265.33 | 0.62% down | 63% down | ||
| 31 | Oruka TherapeuticsORKA · Health Care | NOK 4.6B | NOK 64.5B | NOK 951.08 | 1.91% up | 255% up | ||
| 32 | Arrowhead PharmaceuticalsARWR · Health Care | NOK 4.5B | NOK 60.2B | NOK 425.49 | 1.25% up | 13% up | ||
| 33 | Definium TherapeuticsDFTX · Health Care | NOK 3.2B | NOK 39.3B | NOK 287.36 | 1.24% up | 168% up | ||
| 34 | ErascaERAS · Health Care | NOK 3.2B | NOK 48.6B | NOK 138.61 | 3.34% up | 395% up | ||
| 35 | Mirum PharmaceuticalsMIRM · Health Care | NOK 3.1B | NOK 60.8B | NOK 931.00 | 3.27% up | 34% up | ||
| 36 | Rhythm PharmaceuticalsRYTM · Health Care | NOK 1.4B | NOK 78.9B | NOK 1,138.53 | 1.88% down | 18% up | ||
| 37 | Travere TherapeuticsTVTX · Health Care | NOK 1.1B | NOK 45.2B | NOK 470.81 | 3.86% down | 45% up | ||
| 38 | Axsome TherapeuticsAXSM · Health Care | NOK 860.7M | NOK 69.6B | NOK 1,322.57 | 1.25% up | 6% down | ||
| 39 | Amneal PharmaceuticalsAMRX · Health Care | -NOK 690.1M | NOK 72.6B | NOK 208.50 | 2.24% down | 90% up | ||
| 40 | VeradermicsMANE · Health Care | -NOK 1.2B | NOK 51.2B | NOK 1,212.52 | 0.38% down | 231% up | ||
| 41 | PTC TherapeuticsPTCT · Health Care | -NOK 2B | NOK 47.5B | NOK 568.54 | 3.16% down | 21% down | ||
| 42 | CytokineticsCYTK · Health Care | -NOK 6.4B | NOK 69.9B | NOK 501.62 | 0.27% up | 19% down | ||
| 43 | BridgeBio PharmaBBIO · Health Care | -NOK 20.3B | NOK 148.5B | NOK 762.08 | 0.22% up | 21% up | ||
| 44 | AbbVieABBV · Health Care | -NOK 31.9B | NOK 4.89T | NOK 2,763.87 | 0.86% down | 25% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 9.7477 NOK).
Questions and answers
Which pharmaceutical companies in the United States rank first by net assets?
Pfizer (NOK 842.9B), Johnson & Johnson (NOK 794.9B) and Merck & Co (NOK 512.8B) are the top three of the 44 pharmaceutical companies in the United States ranked by net assets as of 20 Nov 2026, 06:58 UTC.
How many pharmaceutical companies in the United States are in this ranking?
44 are ranked by net assets.
What are these pharmaceutical companies in the United States worth together?
The 44 pharmaceutical companies in the United States ranked by net assets have a combined market value of NOK 36.42T as of 20 Nov 2026, 06:58 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by net assets”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.